Literature DB >> 27268129

Time to seroconversion of HBsAg to anti-HBs in individuals who lost HBsAg during follow-up.

M R H Roushan1, M Mohammadpour1, M Baiany1, S Soleimani2, A Bijani1.   

Abstract

To determine the time to appearance of antibody against hepatitis B surface antigen (anti-HBs) after clearance of hepatitis B surface antigen (HBsAg) in chronically infected individuals, we followed up 3963 cases with positive antibody against hepatitis B e antigen (anti-HBe) from 1991 to 2014. Of these, 101 (67 males, 34 females) lost HBsAg. These serocleared cases were checked every 6-month interval regarding HBsAg, anti-HBs, liver function tests, and liver sonography. Hepatitis B virus DNA was assessed at the time of seroclearance or the appearance of anti-HBs. The mean age of these patients at entry to this study was 34·4 ± 13 years. The mean follow-up duration until seroclearance of HBsAg was 6·6 ± 4·3 years. After the mean follow-up of 43·7 ± 45 months, anti-HBs appeared in 64 (63·4%) cases. The cumulative probabilities of anti-HBs appearance for 2, 5 and 10 years were 24·3%, 58% and 78·2%, respectively. The appearance of anti-HBs was associated with age ⩾35 years and seroclearance of HBsAg (hazard ratio 1·96, 95% confidence interval 1·32-3·38, P = 0·016) but not with sex. The results show that anti-HBs may develop in 78·2% of cases within 10 years of HBsAg clearance. Age ⩾35 years at HBsAg loss was associated with earlier development of anti-HBs.

Entities:  

Keywords:  Clearance; HBsAg; chronic hepatitis B; follow-up; resolved hepatitis B

Mesh:

Substances:

Year:  2016        PMID: 27268129      PMCID: PMC9150472          DOI: 10.1017/S0950268816001217

Source DB:  PubMed          Journal:  Epidemiol Infect        ISSN: 0950-2688            Impact factor:   4.434


  23 in total

1.  Clearance of HBsAg in seven patients with chronic hepatitis B.

Authors:  H Adachi; S Kaneko; E Matsushita; Y Inagaki; M Unoura; K Kobayashi
Journal:  Hepatology       Date:  1992-12       Impact factor: 17.425

2.  Factors associated with natural seroclearance of hepatitis B surface antigen and prognosis after seroclearance: a prospective follow-up study.

Authors:  Jeong Hwan Kim; Joon Hyoek Lee; Sang Jong Park; Mun Hee Bae; Ji Hyang Kim; Do Young Kim; Jong Kyu Kim; Moon Seok Choi; Kwang Cheol Koh; Seung Woon Paik; Byung Chul Yoo
Journal:  Hepatogastroenterology       Date:  2008 Mar-Apr

3.  Long-term clinical and histological outcomes in patients with spontaneous hepatitis B surface antigen seroclearance.

Authors:  Sang Hoon Ahn; Young Nyun Park; Jun Yong Park; Hye-Young Chang; Jung Min Lee; Ji Eun Shin; Kwang-Hyub Han; Chanil Park; Young Myoung Moon; Chae Yoon Chon
Journal:  J Hepatol       Date:  2005-02       Impact factor: 25.083

4.  Factors associated with spontaneous HBsAg clearance in chronic hepatitis B patients followed at a university hospital.

Authors:  Sandro C Ferreira; Silvana G F Chachá; Fernanda F Souza; Andreza C Teixeira; Rodrigo C Santana; Márcia G Villanova; Sérgio Zucoloto; Leandra N Ramalho; Gleici S C Perdoná; Afonso D C Passos; Ana L C Martinelli
Journal:  Ann Hepatol       Date:  2014 Nov-Dec       Impact factor: 2.400

5.  Clearance of hepatitis B surface antigen and risk of hepatocellular carcinoma in a cohort chronically infected with hepatitis B virus.

Authors:  Josephine Simonetti; Lisa Bulkow; Brian J McMahon; Chriss Homan; Mary Snowball; Susan Negus; James Williams; Stephen E Livingston
Journal:  Hepatology       Date:  2010-05       Impact factor: 17.425

Review 6.  Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures.

Authors:  D Lavanchy
Journal:  J Viral Hepat       Date:  2004-03       Impact factor: 3.728

7.  Sero-clearance of hepatitis B surface antigen in chronic carriers does not necessarily imply a good prognosis.

Authors:  T I Huo; J C Wu; P C Lee; G Y Chau; W Y Lui; S H Tsay; L T Ting; F Y Chang; S D Lee
Journal:  Hepatology       Date:  1998-07       Impact factor: 17.425

8.  Significance of isolated antibody to hepatitis B core antigen determined by immune response to hepatitis B vaccination.

Authors:  M Draelos; T Morgan; R B Schifman; R E Sampliner
Journal:  JAMA       Date:  1987-09-04       Impact factor: 56.272

9.  Natural history of chronic HBV carriers in northern Italy: morbidity and mortality after 30 years.

Authors:  Mauro Manno; Calogero Cammà; Filippo Schepis; Fabio Bassi; Roberta Gelmini; Francesco Giannini; Francesca Miselli; Antonella Grottola; Ilva Ferretti; Chiara Vecchi; Marisa De Palma; Erica Villa
Journal:  Gastroenterology       Date:  2004-09       Impact factor: 22.682

10.  HBsAg Seroclearance in chronic hepatitis B in Asian patients: replicative level and risk of hepatocellular carcinoma.

Authors:  Man-Fung Yuen; Danny Ka-Ho Wong; James Fung; Philip Ip; David But; Ivan Hung; Kevin Lau; John Chi-Hang Yuen; Ching-Lung Lai
Journal:  Gastroenterology       Date:  2008-07-16       Impact factor: 22.682

View more
  4 in total

1.  Use of ELISpot assay to study HBs-specific B cell responses in vaccinated and HBV infected humans.

Authors:  Chen Tian; Yuxin Chen; Yong Liu; Shixia Wang; Yang Li; Guiyang Wang; Juan Xia; Xiang-An Zhao; Rui Huang; Shan Lu; Chao Wu
Journal:  Emerg Microbes Infect       Date:  2018-02-16       Impact factor: 7.163

2.  Spontaneous relapse in patients with inactive chronic hepatitis B virus infection.

Authors:  Mojhde Karajibani; Mohammad Reza Hasanjani Roushan; Masomeh Bayani; Mostafa Javanian; Jila Masrour-Roudsari
Journal:  Caspian J Intern Med       Date:  2018

3.  Understanding the patient population and test utilization for hepatitis B virus testing.

Authors:  Rihwa Choi; Yejin Oh; Seungman Park; Sang Gon Lee; Eun Hee Lee
Journal:  J Clin Lab Anal       Date:  2019-09-30       Impact factor: 2.352

4.  Durability of Hepatitis B Surface Antigen Loss With Nucleotide Analogue and Peginterferon Therapy in Patients With Chronic Hepatitis B.

Authors:  Anna S Lok; Fabien Zoulim; Geoffrey Dusheiko; Henry L Y Chan; Maria Buti; Marc G Ghany; Anuj Gaggar; Jenny C Yang; George Wu; John F Flaherty; G Mani Subramanian; Stephen Locarnini; Patrick Marcellin
Journal:  Hepatol Commun       Date:  2019-10-10
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.